opdivo
Japan announces measure to crack down on drug pricing
December 20, 2016Manufacturing and Production, Medical Communications Japan, Shinzo Abe, opdivo
Japan has committed to annual drug price reviews whilst also expanding the scope by which the prices are deemed to …
BMS shares promising Opdivo/Yervoy data for advanced bladder cancer
December 8, 2016Research and Development BMS, Yervoy, opdivo
BMS has revealed new efficacy data on the combination of its immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment …
Japan to slash Opdivo costs by 50%
November 17, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Japan, opdivo
Japan’s health ministry has announced it is to slash the price of Bristol-Myers Squibb’s Opdivo by 50% in the country …
Blood cancer sufferers to receive early access to BMS’ Opdivo
November 3, 2016Medical Communications Bristol-Myers Squibb, lyphoma, opdivo
Bristol-Myers Squibb has announced that their immunotherapy drug, Opdivo (nivolumab), will be made available to patients in the UK through …
BMS unveils reorganisation plans & boosted profits
October 28, 2016Business Services, Medical Communications Bristol-Myers Squibb, Yervoy, opdivo
BMS has announced its intention to restructure its operations alongside $3 billion share buyback and quarterly results which exceeded expectations.The …
MSD’s Keytruda given first FDA approval for first line treatment
October 25, 2016Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo
MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …
FDA accepts another Opdivo indication for priority review
October 24, 2016Sales and Marketing BMS, Bristol-Myers Squibb, FDA, opdivo
The FDA has accepted a supplemental Biologics License Application (sBLA) for Bristol-Myers Squibb’s Opdivo for treatment of locally advanced unresectable …
MSD’s Keytruda early success ends trial early
October 24, 2016Sales and Marketing MSD, Merck, Roche, keytruda, opdivo, tecentriq
MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …
Failure for BMS’ Opdivo in lung cancer trial
October 10, 2016Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq
Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …
Roche’s lung cancer success spells competition for BMS’ Opdivo
October 10, 2016Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq
Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …
FDA to review MSD’s Keytruda as a first-line lung cancer treatment
September 7, 2016Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo
The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …
Roche’s Tecentriq meets primary endpoints in Phase III lung cancer trial
September 1, 2016Research and Development PD-L1, Roche, keytruda, nivolumab, opdivo, phase III, tecentriq
Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall …
The September issue of Pharmafocus is now live!
August 31, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myer's Squibb, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, Cloud Computing, Pharmafocus, Pharmafocus new issue, brexit, clinical trial transparaency, opdivo
The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …
SMC reverses decision on Opdivo in advanced skin cancer
August 8, 2016Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer
The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …
Opdivo and Keytruda set for India launches by end of year
August 8, 2016Sales and Marketing India, keytruda, launch, opdivo
Indian cancer patients could be set to receive two of the world’s leading oncology drugs, MSD’s Keytruda and Bristol-Myers Squibb’s …
